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Background
The purpose of this study was to evaluate the association
of polymorphisms of ATM and TP53 genes in prostate
cancer patients with morbidity after radiotherapy. These
two genes encode important proteins of the DNA repair
pathways. It is believed that their polymorphisms are likely
to modify the response of normal tissues to radiation.
Patients and methods
After signing the informed consent agreement, a sample of
peripheral blood of 50 patients from Araújo Jorge Hospital
was collected to verify the presence of a ATM (rs1801516),
TP53 (rs1042522, rs1800371, rs17878362, rs17883323 and
rs35117667) and MDM2 (rs2279744) polymorphisms. The
side effects were classified according to the Radiation
Therapy Oncology Group (RTOG) score.
Results
On univariate analysis, hypertension was strongly asso-
ciated with a decreased risk of late urinary toxicities (OR=
0,048, 95% CI 0,004 - 0,620; p= 0,022). Patients receiving
hormone therapy had a significantly higher incidence of
acute skin toxicity (OR= 27,667 95%CI:1,203-636,11; p =
0,029). The exchange C>T in the position 11322 (intron 3)
of the TP53 gene (rs35117667) was significantly associated
with the risk of acute skin toxicity (OR=0,012 95% CI
0,0004-0,317; p=0,006). No significant associations were
found for the remaining polymorphisms (p>0,05).
Conclusion(s)
We conclude that hypertension seems to be protective
for late urinary effects of radiotherapy. Hormonal therapy
and the intronic TP53 polymorphism, rs35117667, were
associated to increased acute skin radiosensitivity. This
observation corroborates the importance of investigating
the genetic profile to predict adverse side effects in
patients undergoing radiotherapy.
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